Acurx Pharmaceuticals, Inc.
ACXP
$1.42
-$0.01-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.21% | -12.88% | -32.17% | -1.81% | -24.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.65% | -21.16% | -42.12% | -28.23% | -44.94% |
| Operating Income | -1.65% | 21.16% | 42.12% | 28.23% | 44.94% |
| Income Before Tax | -0.35% | 21.78% | 43.26% | 29.37% | 45.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.35% | 21.78% | 43.26% | 29.37% | 45.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.35% | 21.78% | 43.26% | 29.37% | 45.50% |
| EBIT | -1.65% | 21.16% | 42.12% | 28.23% | 44.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 71.96% | 71.17% | 77.85% | 64.46% | 63.77% |
| Normalized Basic EPS | 71.95% | 71.17% | 77.85% | 64.46% | 63.77% |
| EPS Diluted | 71.96% | 71.17% | 77.85% | 64.46% | 63.77% |
| Normalized Diluted EPS | 71.95% | 71.17% | 77.85% | 64.46% | 63.77% |
| Average Basic Shares Outstanding | 257.85% | 171.32% | 156.16% | 98.70% | 50.44% |
| Average Diluted Shares Outstanding | 257.85% | 171.32% | 156.16% | 98.70% | 50.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |